Oxford BioTherapeutics (OBT) has entered into a number of collaborations to develop targeted medicines and diagnostics based on its unique OGAP®
database which enables the identification of best in class targets and biomarkers.
2011
OBT has entered into a license agreement to provide OBT with access to BioWa’s patented POTELLIGENT® Technology platform
for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. OBT intends to use
POTELLIGENT® Technology to develop, manufacture and commercialize selected ADCC programs from its pipeline of preclinical
antibodies for oncology. The deal forms part of OBT’s strategy to combine its novel proprietary oncology targets with
world-leading antibody technologies, to develop highly efficacious new cancer drugs for patients with few treatment options.
|
OBT has out-licensed one of its internal preclinical antibody programs to sanofi-aventis in its most advanced antibody licensing deal to date.
sanofi-aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by OBT, to develop,
manufacture and commercialize antibody drug conjugate (ADC) products for the treatment of cancer. ADC products comprise toxins attached
to antibodies which form effective therapeutic products that attack tumor cells in a highly targeted manner. The initiative integrates
OBT’s expertise in cancer target and antibody discovery with the in-house antibody development capabilities of sanofi-aventis.
2009
OBT has entered into a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer. Under the alliance, GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will develop one of its own monoclonal antibodies through to clinical proof of concept, at which point GSK will have an exclusive option to in-license.
2007
OBT has entered into a strategic collaboration with Amgen to discover, develop and
commercialise novel therapeutic antibodies for the treatment of cancer. This new
collaboration will enable OBT to further strengthen its pipeline of fully human therapeutic
antibodies in cancer based on the target discovery capabilities of its unique OGAP
®
database.
OBT has entered a three way arrangement with Medarex Inc. and Biosite Inc. This unique agreement extends OBT
discovery & development capabilities to allow it to build its own pipeline of therapeutic antibodies. Biosite will carry out
the early stage antibody generation on behalf of OBT using Medarex’ proprietary transgenic mouse technology under
a license agreement.
OBT also extended its collaboration with Biosite to cover the development of a novel blood based diagnostic
for ovarian cancer. This agreement follows an initial collaboration signed in 2006 in the field of colorectal cancer.
2006
OBT and Medarex Inc. formed a strategic collaboration to discover and develop new human antibody therapeutics for
the treatment of cancers including colorectal cancer (CRC). The collaboration provides for OBT and Medarex to discover,
develop and commercialize therapeutic antibodies on a 50:50 basis.
OBT signed a collaboration with Biosite
® Inc. for the evaluation of protein-based disease markers for colorectal cancer.
The markers could be used for the development of potential blood-based diagnostic products aimed at expanding personalised
therapeutic options for colorectal cancer. In particular, these blood-based diagnostics would be designed to enable the
early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate
therapeutic option.
